Table 4.
Clinical characteristics of the mutated and non-mutated groups
| Clinical Features | Non-mutated group (n = 17) | Gene mutated group (n = 31) | P vaue |
|---|---|---|---|
| Age (years) | 3.77 ± 3.90 | 5.35 ± 2.92 | 0.035 |
| MP-DNA × 105(copies/mL) | 6. 59 ± 2.41 | 35. 88 ± 12.47 | < 0.001 |
| White blood cell count (× 10/L9) | 6.91 ± 2.89 | 7.85 ± 4.91 | 0.635 |
| Procalcitonin (ng/mL) | 1.23 ± 1.81 | 1.81 ± 2.74 | 0.140 |
| Ultrasensitive C-reactive protein (mg/mL) | 23.85 ± 42.26 | 42.66 ± 62.45 | 0.030 |
| Lactate dehydrogenase (U/L) | 686.06 ± 635.33 | 691.36 ± 600.13 | 0.796 |
| Duration of cough (days) | 15.06 ± 7.69 | 16.90 ± 8.35 | 0.545 |
| Fever duration (days) | 9.12 ± 7.83 | 12.68 ± 6.80 | 0.024 |
| Length of hospitalization (days) | 12.00 ± 7.21 | 15.58 ± 6.88 | 0.027 |
| Duration of macrolide application (days) | 7.47 ± 3.47 | 10.10 ± 4.96 | 0.034 |
| Time to fever remission after macrolide application (days) | 3.88 ± 3.87 | 6.47 ± 3.79 | 0.023 |
P > 0.05 indicates no statistically significant difference between the two groups, and P < 0.05 indicates a statistically significant difference between the two groups